Can I Take Omega-3 (EPA/DHA) With PT-141 (Bremelanotide)?
At a glance
- Interaction listed in the Vyleesi label / None for omega-3; the named oral interaction is naltrexone
- Bremelanotide clearance / Hydrolysis of amide bonds; terminal half-life about 2.7 hours [1]
- Bleeding / The omega-3 label says omega-3 acids may prolong bleeding time; monitor if an anticoagulant or antiplatelet drug is also taken [2]
- Atrial fibrillation / More AF above 1 g/day in a meta-analysis (HR 1.49) [3]
- Timing / No separation described; Vyleesi is used as needed at least 45 minutes before anticipated sexual activity [1]
Does the Vyleesi label list omega-3 or fish oil as an interaction?
No. Section 7 of the Vyleesi prescribing information covers two interaction issues, and omega-3 appears in neither [1]. The first is general: bremelanotide may slow gastric emptying and so reduce the rate and extent of absorption of oral medicines. The label says to avoid Vyleesi with oral drugs that depend on threshold blood concentrations, such as antibiotics, and to consider skipping it when a fast effect from an oral medicine such as indomethacin is wanted [1]. The second is specific: Vyleesi may significantly decrease exposure to oral naltrexone, and the label says to avoid that pairing when naltrexone is used for alcohol or opioid addiction [1]. In clinical pharmacology studies, only naltrexone and indomethacin were meaningfully affected [1].
How is bremelanotide metabolized?
Bremelanotide is a cyclic peptide of seven amino acids [1]. After the 1.75 mg subcutaneous dose, mean Cmax is 72.8 ng/mL, median Tmax is about 1 hour, absolute bioavailability is about 100%, and mean terminal half-life is about 2.7 hours [1]. The label describes metabolism by hydrolysis of amide bonds, with 64.8% of radioactivity recovered in urine and 22.8% in feces [1]. The omega-3-acid ethyl esters label separately says clinically significant CYP-mediated inhibition by EPA/DHA combinations is not expected in humans [2].
What the omega-3 label says about bleeding
The omega-3-acid ethyl esters label says omega-3 acids may prolong bleeding time. It says patients taking the product with an anticoagulant or another drug affecting coagulation, such as an antiplatelet agent, should be monitored periodically [2]. The same label states that the bleeding-time prolongation reported in trials did not exceed normal limits and did not produce clinically significant bleeding episodes, and that clinical trials have not thoroughly examined the combination with anticoagulants [2]. It also says to use caution in people with known fish or shellfish allergy, noting it is not known whether they are at higher risk [2].
How large is the omega-3 bleeding signal?
The Vascepa label reports that in REDUCE-IT (4 g/day icosapent ethyl), any bleeding occurred in 12% of patients on Vascepa versus 10% on placebo, and serious bleeding in 3% versus 2%. Bleeding was more frequent in people also taking aspirin, clopidogrel or warfarin.
In one small pilot study of 10 healthy volunteers, 28 days of a prescription omega-3 product at 4 capsules a day did not inhibit platelet aggregation with any agonist on its own. Combined with aspirin, it inhibited aggregation with every agonist tested except TRAP [4].
The Vyleesi warnings section covers transient blood pressure increase and heart rate reduction, focal hyperpigmentation and nausea, not bleeding [1].
What high-dose omega-3 does on its own
Atrial fibrillation is a documented hazard of high-dose fish oil. A meta-analysis of 7 randomized cardiovascular-outcome trials with 81,210 patients found more atrial fibrillation with marine omega-3 (HR 1.25, 95% CI 1.07 to 1.46). The effect was larger above 1 g/day (HR 1.49, 95% CI 1.04 to 2.15) than at 1 g/day or less (HR 1.12, 95% CI 1.03 to 1.22) [3]. The Vascepa label reports that in REDUCE-IT, atrial fibrillation or flutter requiring hospitalization of 24 hours or more occurred in 3% of patients on icosapent ethyl versus 2% on placebo. The omega-3-acid ethyl esters label describes a possible association with more frequent symptomatic atrial fibrillation or flutter in people who already have paroxysmal or persistent AF, particularly in the first 2 to 3 months. It is based on a 663-person trial where the combined hazard ratio was 1.25 [2].
Over-the-counter fish oil is a dietary supplement containing EPA and DHA [5]. Prescription omega-3-acid ethyl esters are a distinct product, labeled as an adjunct to diet for adults with triglycerides of at least 500 mg/dL. Their effect on cardiovascular mortality and morbidity has not been determined [2].
Timing and dose
Vyleesi is 1.75 mg injected subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. The label allows no more than one dose in 24 hours and says more than 8 doses a month is not recommended [1]. Neither label describes a reason to space the injection away from fish oil capsules.
Frequently asked questions
Can I take fish oil while using PT-141 (bremelanotide)?
Does omega-3 change how PT-141 is absorbed?
Does fish oil raise bleeding risk with PT-141?
Is prescription omega-3 different from a fish oil capsule?
Do I need to space fish oil away from a PT-141 injection?
References
Show all 7 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. National Library of Medicine, DailyMed. Omega-3-acid ethyl esters capsules (Lovaza-type generic) prescribing information. Omega-3-acid ethyl esters capsules (Lovaza-type generic) label
- Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation. 2021;144(25):1981-1990.
- Larson MK, Ashmore JH, Harris KA, Vogelaar JL, Pottala JV, Sprehe M, et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost. 2008;100(4):634-41.
- Omega-3 Supplements: What You Need To Know | NCCIH.
- Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. 2009;136(1):4-16.
- U.S. Federal Register. Public inspection document 2026-22192 (compounded drugs and FDA review). Federal Register public inspection 2026-22192